Roche’s Perjeta nabs speedy FDA nod in early breast cancer

Tracy Staton

is now the first drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive cancer, Perjeta can now reach a huge new group of patients at stages of the disease.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS